UY26723A1 - Moléculas mutantes de ctla4 solubles y usos de las mismas - Google Patents

Moléculas mutantes de ctla4 solubles y usos de las mismas

Info

Publication number
UY26723A1
UY26723A1 UY26723A UY26723A UY26723A1 UY 26723 A1 UY26723 A1 UY 26723A1 UY 26723 A UY26723 A UY 26723A UY 26723 A UY26723 A UY 26723A UY 26723 A1 UY26723 A1 UY 26723A1
Authority
UY
Uruguay
Prior art keywords
soluble ctla4
mutant molecules
amino acid
molecules
ctla4 mutant
Prior art date
Application number
UY26723A
Other languages
English (en)
Spanish (es)
Inventor
Peter S Linsley
Bajorath Jurgen
Robert J Peach
Joseph R Naemura
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26723A1 publication Critical patent/UY26723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY26723A 2000-05-26 2001-05-23 Moléculas mutantes de ctla4 solubles y usos de las mismas UY26723A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
UY26723A1 true UY26723A1 (es) 2001-12-28

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26723A UY26723A1 (es) 2000-05-26 2001-05-23 Moléculas mutantes de ctla4 solubles y usos de las mismas

Country Status (41)

Country Link
EP (3) EP1248802B9 (OSRAM)
JP (1) JP4328525B2 (OSRAM)
KR (2) KR100895134B1 (OSRAM)
CN (2) CN101255192A (OSRAM)
AR (1) AR031699A1 (OSRAM)
AT (1) ATE271066T1 (OSRAM)
AU (2) AU6346601A (OSRAM)
BE (1) BE2011C041I2 (OSRAM)
BR (1) BRPI0111191B8 (OSRAM)
CA (1) CA2409748C (OSRAM)
CY (2) CY2011019I1 (OSRAM)
CZ (1) CZ304451B6 (OSRAM)
DE (2) DE60104282T2 (OSRAM)
DK (1) DK1248802T3 (OSRAM)
EC (1) ECSP024365A (OSRAM)
EE (2) EE05458B1 (OSRAM)
EG (1) EG24459A (OSRAM)
ES (2) ES2571852T3 (OSRAM)
FR (1) FR11C0053I2 (OSRAM)
GE (1) GEP20053658B (OSRAM)
HK (1) HK1048126B (OSRAM)
HU (2) HU228137B1 (OSRAM)
IL (1) IL152315A (OSRAM)
LT (1) LT5133B (OSRAM)
LU (1) LU91902I2 (OSRAM)
LV (1) LV12994B (OSRAM)
MX (1) MXPA02011534A (OSRAM)
MY (1) MY136113A (OSRAM)
NO (2) NO330797B1 (OSRAM)
PE (1) PE20011338A1 (OSRAM)
PL (1) PL206267B1 (OSRAM)
PT (1) PT1248802E (OSRAM)
RU (1) RU2283847C2 (OSRAM)
SI (1) SI1248802T1 (OSRAM)
SK (1) SK288131B6 (OSRAM)
TR (1) TR200402703T4 (OSRAM)
TW (2) TWI314933B (OSRAM)
UA (1) UA87432C2 (OSRAM)
UY (1) UY26723A1 (OSRAM)
WO (1) WO2001092337A2 (OSRAM)
ZA (1) ZA200208944B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
EA024877B1 (ru) * 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
SG192905A1 (en) 2011-02-23 2013-09-30 Amgen Inc Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
SG10201609447XA (en) * 2012-05-11 2017-01-27 Medimmune Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) * 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
EA202191909A1 (ru) 2014-01-13 2022-01-31 Эмджен Инк. Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
JP6695814B2 (ja) 2014-06-04 2020-05-20 アムジエン・インコーポレーテツド 哺乳類細胞培養物を回収するための方法
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN111031790A (zh) 2017-04-20 2020-04-17 E开创生物技术股份有限公司 产生基因修改的动物的方法
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
KR20230152810A (ko) 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
WO2021258017A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
JP2023537670A (ja) 2020-07-28 2023-09-05 シージェン インコーポレイテッド ポリペプチドを生産するための方法及びシステム
CN118647416A (zh) 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
KR20240167717A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 세포 배양 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis

Also Published As

Publication number Publication date
EP1536234B1 (en) 2016-03-16
PL206267B1 (pl) 2010-07-30
NO2011027I1 (no) 2012-01-09
AU2001263466B2 (en) 2006-04-27
LT2002114A (en) 2003-12-29
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
HK1048126B (en) 2005-03-04
TW200906857A (en) 2009-02-16
UA87432C2 (uk) 2009-07-27
EG24459A (en) 2009-07-16
PT1248802E (pt) 2004-11-30
TWI314933B (en) 2009-09-21
BR0111191A (pt) 2004-07-06
ZA200208944B (en) 2004-02-13
IL152315A0 (en) 2003-05-29
DE122011100063I1 (de) 2012-06-14
WO2001092337A3 (en) 2002-05-10
CY1117625T1 (el) 2017-04-26
KR20030009502A (ko) 2003-01-29
EP1248802B1 (en) 2004-07-14
JP4328525B2 (ja) 2009-09-09
MXPA02011534A (es) 2004-08-12
BRPI0111191B8 (pt) 2021-05-25
NO2011027I2 (OSRAM) 2011-12-15
KR100889887B1 (ko) 2009-03-24
RU2283847C2 (ru) 2006-09-20
WO2001092337A2 (en) 2001-12-06
SK288131B6 (sk) 2013-10-02
GEP20053658B (en) 2005-11-10
EP1536234A3 (en) 2009-06-03
CZ304451B6 (cs) 2014-05-14
CA2409748C (en) 2008-09-16
AU6346601A (en) 2001-12-11
NO20025656L (no) 2002-11-25
TR200402703T4 (tr) 2004-11-22
ES2571852T3 (es) 2016-05-27
CA2409748A1 (en) 2001-12-06
MY136113A (en) 2008-08-29
AU2001263466C1 (en) 2006-10-26
SK15702002A3 (sk) 2004-01-08
FR11C0053I2 (fr) 2013-01-11
HU228137B1 (en) 2012-12-28
TWI319405B (en) 2010-01-11
PE20011338A1 (es) 2002-01-13
CY2011019I1 (el) 2016-12-14
CN1441810A (zh) 2003-09-10
HK1048126A1 (en) 2003-03-21
CZ20023892A3 (cs) 2003-09-17
HUS1300012I1 (hu) 2016-08-29
SI1248802T1 (en) 2005-02-28
JP2004511213A (ja) 2004-04-15
FR11C0053I1 (OSRAM) 2012-01-13
IL152315A (en) 2010-04-15
HUP0302201A3 (en) 2010-01-28
LV12994B (en) 2003-08-20
EP1536234A2 (en) 2005-06-01
DE60104282D1 (de) 2004-08-19
LT5133B (lt) 2004-05-25
EP3029062A1 (en) 2016-06-08
HK1071931A1 (en) 2005-08-05
EP1248802B9 (en) 2005-05-11
ES2225549T3 (es) 2005-03-16
EE05557B1 (et) 2012-08-15
NO330797B1 (no) 2011-07-18
BE2011C041I2 (OSRAM) 2020-08-20
EE201100050A (et) 2011-10-17
EE05458B1 (et) 2011-08-15
KR100895134B1 (ko) 2009-05-04
ECSP024365A (es) 2003-03-31
AR031699A1 (es) 2003-10-01
CN1309735C (zh) 2007-04-11
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
PL366231A1 (en) 2005-01-24
BRPI0111191B1 (pt) 2019-12-31
NO20025656D0 (no) 2002-11-25
HUP0302201A2 (hu) 2003-10-28
EE200200659A (et) 2004-06-15
DE60104282T2 (de) 2005-10-13
CN101255192A (zh) 2008-09-03
DK1248802T3 (da) 2004-11-15
ATE271066T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
UY26723A1 (es) Moléculas mutantes de ctla4 solubles y usos de las mismas
DE60131021D1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
BR0107691A (pt) Sapogeninas substituìdas e seu uso
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
DK0842934T3 (da) 5-HT1F agonister
CY1105944T1 (el) Βιοαποικοδομησιμα αλγινικα πηκτωματα παρατεταμενης εκλυσης
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
CY1105020T1 (el) Υποκαταστατες διαζεπανες
SE0003476D0 (sv) Compounds
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
DE50309342D1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
NO20002408D0 (no) 5-HT1F antagonister

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20140306

VENC Patent expired

Effective date: 20210523